{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:02:58Z","timestamp":1789448578232,"version":"build-2803163510"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tenecteplase (TNK) has emerged as a promising alternative to alteplase (tPA) for intravenous thrombolysis in acute ischemic stroke (AIS). This study aimed to evaluate the efficacy and safety of TNK compared with tPA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following the PRISMA 2020 guidelines, PubMed, Web of Science, Cochrane Central, EBSCO, and Scopus were systematically searched from inception through January 2026 to identify randomized controlled trials (RCTs) and observational studies comparing TNK with tPA in adults with AIS. Effect estimates were pooled using fixed- or random-effects models according to the degree of heterogeneity and were reported as risk ratios (RRs), odds ratios (ORs), or mean differences (MDs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-four studies (6 RCTs and 18 observational studies; total\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f20,592) involving patients with AIS were included. Compared with tPA, TNK was associated with a greater likelihood of excellent functional recovery (mRS 0\u20131) at 90\u202fdays (RR\u202f=\u202f1.08; 95% CI: 1.01\u20131.15;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.02) and a shorter door-to-needle time by an average of 4\u202fmin (MD\u202f=\u202f\u22124.20; 95% CI: \u22127.77 to \u22120.64;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.02). Mortality was lower among patients treated with TNK (OR\u202f=\u202f0.83; 95% CI: 0.73\u20130.94;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004). However, subgroup analyses restricted to RCTs showed no significant difference in mortality between the TNK and tPA groups (OR\u202f=\u202f0.99; 95% CI: 0.82\u20131.21;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.95).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TNK provides efficacy and safety profiles comparable to those of tPA while offering a greater likelihood of excellent functional recovery, faster treatment initiation, and lower mortality in observational studies. Further high-quality RCTs are warranted to confirm these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>CRD420251030320.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1921538","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:27:03Z","timestamp":1789446423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tenecteplase in acute ischemic stroke: an updated meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hussain","family":"Almohammed","sequence":"first","affiliation":[{"name":"College of Medicine, King Faisal University","place":["Al Ahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Salah","family":"Morad","sequence":"additional","affiliation":[{"name":"General Medicine Practice, Batterjee Medical College","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra Wadi","family":"Bin Saddiq","sequence":"additional","affiliation":[{"name":"General Medicine Practice, Batterjee Medical College","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah Ibrahim","family":"Almuhaysin","sequence":"additional","affiliation":[{"name":"College of Medicine, King Faisal University","place":["Al Ahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayan Mohammed Khair","family":"Al Zoabi","sequence":"additional","affiliation":[{"name":"General Medicine Practice, Batterjee Medical College","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wejdan Ahmed","family":"Aldawsari","sequence":"additional","affiliation":[{"name":"College of Medicine, Tabuk University","place":["Tabuk, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanveer Nidal","family":"Khan","sequence":"additional","affiliation":[{"name":"General Medicine Practice, Batterjee Medical College","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husna Irfan","family":"Thalib","sequence":"additional","affiliation":[{"name":"General Medicine Practice, Batterjee Medical College","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Alabdi","sequence":"additional","affiliation":[{"name":"Neurology Department, King Fahad Hospital","place":["Al Ahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1212\/WNL.0000000000012781","article-title":"Global epidemiology of stroke and access to acute ischemic stroke interventions","volume":"97","author":"Saini","year":"2021","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"593887","DOI":"10.3389\/fneur.2021.593887","article-title":"Silver jubilee of stroke thrombolysis with alteplase: evolution of the therapeutic window","volume":"12","author":"Pan","year":"2021","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1161\/atvbaha.108.179655","article-title":"The tissue-type plasminogen activator story","volume":"29","author":"Collen","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e001824","DOI":"10.1161\/SVIN.125.001824","article-title":"Food and Drug Administration approval of tenecteplase: what this means for the field of acute stroke treatment","volume":"5","author":"Grotta","year":"2025","journal-title":"Stroke"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11940-022-00733-4","article-title":"Tenecteplase or alteplase: what is the thrombolytic agent of the future?","volume":"24","author":"Mahmood","year":"2022","journal-title":"Curr Treat Options Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e12795","DOI":"10.1002\/rth2.12795","article-title":"Alteplase or tenecteplase for thrombolysis in ischemic stroke: an illustrated review","volume":"6","author":"Zhu","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"107822","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107822","article-title":"Comparative efficacy and safety among different doses of tenecteplase for acute ischemic stroke: a systematic review and network meta-analysis","volume":"33","author":"Srisurapanont","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/STROKEAHA.122.041061","article-title":"Tenecteplase treatment and thrombus characteristics associated with early reperfusion: an EXTEND-IA TNK trials analysis","volume":"54","author":"Yogendrakumar","year":"2023","journal-title":"Stroke"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1161\/STROKEAHA.119.025041","article-title":"Safety and outcomes of tenecteplase in moderate and severe ischemic stroke: results from NOR-TEST","volume":"50","author":"Kvistad","year":"2019","journal-title":"Stroke"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan- a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e2165","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi","year":"2024","journal-title":"Health Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"ref16","volume-title":"Review Manager 5 (RevMan 5) [Computer program]. Version 5.4.","year":"2020"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/00185787241289296","article-title":"Improved door-to-needle time after implementation of Tenecteplase as the preferred thrombolytic for acute ischemic stroke at a large community teaching hospital emergency department","volume":"60","author":"Henderson","year":"2025","journal-title":"Hosp Pharm"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000540750","article-title":"Safety and efficacy comparison of Tenecteplase and Alteplase for clinically suspected large vessel occlusion strokes without thrombectomy","volume":"14","author":"Lo","year":"2024","journal-title":"Cerebrovasc Dis Extra"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1007\/s00415-024-12530-x","article-title":"Tenecteplase versus alteplase before stroke thrombectomy: outcomes after system-wide transitions in Pennsylvania","volume":"271","author":"Hendrix","year":"2024","journal-title":"J Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"107931","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107931","article-title":"Early recanalization after tenecteplase versus alteplase: experience in a large stroke network","volume":"33","author":"Karamchandani","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1474-4422(24)00377-6","article-title":"Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial","volume":"23","author":"Muir","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"101189","DOI":"10.1016\/j.neurad.2024.02.007","article-title":"Tenecteplase versus alteplase before thrombectomy: a comprehensive evaluation of clinical and angiographic impact: insights from the ETIS registry","volume":"51","author":"Zarzour","year":"2024","journal-title":"J Neuroradiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1514915","DOI":"10.3389\/fneur.2024.1514915","article-title":"Safety of tenecteplase vs. alteplase in telestroke: a large multistate experience (STAT)","volume":"15","author":"Figurelle","year":"2025","journal-title":"Front Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/svn-2024-003381","article-title":"Tenecteplase thrombolytic therapy for acute ischaemic stroke in China: a real-world, multicentre, retrospective, controlled study","volume":"10","author":"Liu","year":"2024","journal-title":"Stroke Vasc Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4103\/aian.aian_59_24","article-title":"Comparative analysis of Tenecteplase versus Alteplase in acute ischemic stroke: a multicentric observational study from eastern India","volume":"27","author":"Dutta","year":"2024","journal-title":"Ann Indian Acad Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1386386","DOI":"10.3389\/fneur.2024.1386386","article-title":"Real-world data of tenecteplase vs. alteplase in the treatment of acute ischemic stroke: a single-center analysis","volume":"15","author":"Yao","year":"2024","journal-title":"Front Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1136\/jnis-2022-019662","article-title":"Tenecteplase versus alteplase before mechanical thrombectomy: experience from a US healthcare system undergoing a system-wide transition of primary thrombolytic","volume":"15","author":"Hendrix","year":"2023","journal-title":"J Neurointerv Surg"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4103\/aian.aian_754_22","article-title":"Biosimilar tenecteplase versus alteplase in acute ischemic stroke: a real world study","volume":"26","author":"Mohan","year":"2023","journal-title":"Ann Indian Acad Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/medicina58091169","article-title":"Tenecteplase or alteplase better in patients with acute ischemic stroke due to large vessel occlusion: a single center observational study","volume":"58","author":"Teivane","year":"2022","journal-title":"Medicina"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.4103\/aian.aian_1127_21","article-title":"Tenecteplase and alteplase for thrombolysis of acute ischemic stroke within 4.5 hours: an efficacy and safety study","volume":"25","author":"Dhar","year":"2022","journal-title":"Ann Indian Acad Neurol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/ana.26445","article-title":"Intravenous thrombolysis with tenecteplase for the treatment of acute ischemic stroke","volume":"92","author":"Tsivgoulis","year":"2022","journal-title":"Ann Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3390\/jpm12091525","article-title":"Effectiveness and safety of tecneplase vs. alteplase in the acute treatment of ischemic stroke","volume":"12","author":"Estella","year":"2022","journal-title":"J Pers Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jocn.2021.07.004","article-title":"Comparison of thrombolytic agents in treatment of patients with acute ischemic stroke; findings from a single Centre follow up study in real-life settings","volume":"91","author":"George","year":"2021","journal-title":"J Clin Neurosci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1756286420986727","DOI":"10.1177\/1756286420986727","article-title":"Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion","volume":"14","author":"Psychogios","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"ref35","article-title":"Tenecteplase versus alteplase (TENVALT): a study comparing two thrombolytic agents in acute ischemic stroke","volume":"24","author":"Sundar","year":"2019","journal-title":"Neurol Asia"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2024.14721","article-title":"Tenecteplase vs alteplase for patients with acute ischemic stroke: the ORIGINAL randomized clinical trial","volume":"332","author":"Meng","year":"2024","journal-title":"JAMA"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S1474-4422(24)00206-0","article-title":"Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial","volume":"23","author":"Parsons","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/09727531231193242","article-title":"Tenecteplase versus alteplase in acute ischemic stroke: a systematic review and meta-analysis","volume":"31","author":"Singh","year":"2024","journal-title":"Ann Neurosci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1212\/WNL.0000000000004062","article-title":"Tenecteplase in ischemic stroke offers improved recanalization: analysis of 2 trials","volume":"89","author":"Bivard","year":"2017","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12883-019-1404-5","article-title":"In vitro examination of the thrombolytic efficacy of tenecteplase and therapeutic ultrasound compared to rt-PA","volume":"19","author":"Fr\u00fchwald","year":"2019","journal-title":"BMC Neurol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaneurol.2023.1449","article-title":"Symptomatic intracranial hemorrhage with tenecteplase vs alteplase in patients with acute ischemic stroke: the comparative effectiveness of routine tenecteplase vs alteplase in acute ischemic stroke (CERTAIN) collaboration","volume":"80","author":"Warach","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaneurol.2023.2094","article-title":"Safety and efficacy of tenecteplase compared with alteplase in patients with large vessel occlusion stroke: a prespecified secondary analysis of the ACT randomized clinical trial","volume":"80","author":"Bala","year":"2023","journal-title":"JAMA Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2320285","DOI":"10.1080\/07853890.2024.2320285","article-title":"Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials","volume":"56","author":"Huang","year":"2024","journal-title":"Ann Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1177\/1747493016641112","article-title":"Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials","volume":"11","author":"Huang","year":"2016","journal-title":"Int J Stroke"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1161\/STROKEAHA.119.025080","article-title":"Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials","volume":"50","author":"Burgos","year":"2019","journal-title":"Stroke"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1161\/STROKEAHA.123.044267","article-title":"Effect of time to thrombolysis on clinical outcomes in patients with acute ischemic stroke treated with tenecteplase compared to alteplase: analysis from the AcT randomized controlled trial","volume":"54","author":"Singh","year":"2023","journal-title":"Stroke"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1177\/10600280241300230","article-title":"Evaluation of door-to-needle times between Alteplase and Tenecteplase for acute ischemic stroke at two academic medical centers","volume":"59","author":"Monkemeyer","year":"2025","journal-title":"Ann Pharmacother"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/19418744231167491","article-title":"Use of tenecteplase in acute ischemic stroke in the time of SARS-CoV-2","volume":"13","author":"Ostos","year":"2023","journal-title":"Neurohospitalist"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e000102","DOI":"10.1161\/SVIN.121.000102","article-title":"Tenecteplase improves door-to-needle time in real-world acute stroke treatment","volume":"1","author":"Hall","year":"2021","journal-title":"Stroke Vasc Interv Neurol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1161\/STROKEAHA.122.038950","article-title":"Prospective observational cohort study of tenecteplase versus alteplase in routine clinical practice","volume":"53","author":"Warach","year":"2022","journal-title":"Stroke"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ibneur.2023.03.001","article-title":"Feasibility of switching from alteplase to tenecteplase for stroke thrombolysis\u2013a retrospective cohort analysis","volume":"14","author":"Sj\u00f6gren","year":"2023","journal-title":"IBRO Neurosci Rep"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"107468","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107468","article-title":"Comparative safety of tenecteplase vs alteplase for acute ischemic stroke","volume":"33","author":"Flint","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00415-024-12243-1","article-title":"Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies","volume":"271","author":"Ma","year":"2024","journal-title":"J Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40120-023-00530-4","article-title":"Tenecteplase vs. alteplase for intravenous thrombolytic therapy of acute ischemic stroke: a systematic review and meta-analysis","volume":"12","author":"Shen","year":"2023","journal-title":"Neurol Ther"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"14889","DOI":"10.18632\/aging.205315","article-title":"Tenecteplase versus alteplase for patients with acute ischemic stroke: a meta-analysis of randomized controlled trials","volume":"15","author":"Zhang","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1161\/STROKEAHA.111.644815","article-title":"Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score","volume":"43","author":"Mazya","year":"2012","journal-title":"Stroke"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1161\/STR.0000000000000152","article-title":"Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"48","author":"Yaghi","year":"2017","journal-title":"Stroke"},{"key":"ref61","volume-title":"TNKase - Tnecteplase Kit","year":"2025"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1161\/STROKEAHA.122.040052","article-title":"Bradykinin-mediated angioedema following tenecteplase administration in an acute ischemic stroke","volume":"53","author":"Lapostolle","year":"2022","journal-title":"Stroke"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10072-021-05279-y","article-title":"Related factors with orolingual angioedema after intravenous alteplase in acute ischemic stroke: results from a single-center cohort and meta-analysis","volume":"43","author":"Mas-Serrano","year":"2022","journal-title":"Neurol Sci"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1161\/str.0000000000000356","article-title":"Care of the patient with acute ischemic stroke (prehospital and acute phase of care): update to the 2009 comprehensive nursing care scientific statement: a scientific statement from the American Heart Association","volume":"52","author":"Ashcraft","year":"2009","journal-title":"Stroke"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1921538\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:27:05Z","timestamp":1789446425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1921538\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":64,"alternative-id":["10.3389\/fneur.2026.1921538"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1921538","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1921538"}}